Tirzepatide vs Retatrutide
How they differ
- FDA status. Tirzepatide: FDA-approved as Mounjaro and Zepbound.1,2,3 Retatrutide: In clinical trials; not FDA-approved.4,5,6
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Tirzepatide | Retatrutide |
|---|---|---|
| What it is | A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.1 | An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.4,7 |
| FDA status | FDA-approved FDA-approved as Mounjaro and Zepbound1,2,3 FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.1,2,3 | In clinical trials In clinical trials; not FDA-approved4,5,6 Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.8 | Not among the six peptides the policy lists.8 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 108 ClinicalTrials.gov records and 75 PubMed records collected | 8 ClinicalTrials.gov records and 17 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 2Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 5ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 6FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 7Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗
The Lancet · Official source · Source checked November 14, 2026
- 8HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 10Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 11Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 12Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗
The Lancet · Official source · Source checked November 14, 2026
- 13ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 14ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 15ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026